Julia Lenore Marcus, Ph.D.
This page shows the publications Julia Marcus has written about Antiviral Agents.
Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system. Int J STD AIDS. 2019 06; 30(7):689-695.
Potential Overestimation of Racial Disparities in Response to the 8-Week Ledipasvir/Sofosbuvir Regimen for Hepatitis C Virus Genotype 1 Infection. Gastroenterology. 2018 11; 155(5):1646-1647.e2.
Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population. Public Health Rep. 2018 Jul/Aug; 133(4):452-460.
No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients. Clin Gastroenterol Hepatol. 2018 06; 16(6):927-935.
Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One. 2014; 9(3):e91513.
Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV. HIV Med. 2022 07; 23(6):620-628.
Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk Before and After Introduction of Direct-Acting Antivirals. Cancer Epidemiol Biomarkers Prev. 2021 12; 30(12):2188-2196.
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.